Given the potent proinvasive and prometastatic effects of TGF-β and PAR2, inhibiting PAR2 expression or function in the tumoral or stromal compartments of PDAC tumors is likely to have a strong impact on metastatic disease. This evidence concerns the gene F2RL1 and metastatic neoplasm.